title: Triggering final follicular maturation--hCG, GnRH-agonist or both, when and to whom?
abstract: Controlled ovarian hyperstimulation (COH) which combines GnRH antagonist co-treatment and GnRH-agonist (GnRHa) trigger has become a common tool aiming to eliminate severe early OHSS and to support the concept of an OHSS-free clinic. However, due to the reported significantly reduced clinical, efforts have been made to improve reproductive outcome. One of the suggested optional strategies aiming to improve outcome was the addition of low-dose (1500 IU) HCG bolus, administered, concomitant, 35 h or 5 days after the triggering bolus of GnRHa. All these regimens were demonstrated to rescue the luteal phase, resulting in improved reproductive outcome in patients at risk to develop severe OHSS, compared to GnRHa trigger alone, however, with the questionable ability to eliminate severe OHSS.Moreover, following the observations demonstrating comparable or even better oocyte\embryos quality following GnRHa, compared to hCG trigger, and the different effects of LH and hCG on the downstream signaling of the LH receptor, GnRHa is now offered concomitant to the standard hCG trigger dose to improve oocyte/embryo yield and quality. GnRHa and hCG may be offered either concomitantly, 35-37 h prior to oocyte retrieval (dual trigger), or 40 h and 34 h prior to oocyte retrieval, respectively (double trigger).
authors: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. raoul.orvieto@sheba.health.gov.il.|Department of Obstetrics and Gynecology, Infertility and IVF Unit, Sheba Medical Center, Ramat Gan, 52621, Israel. raoul.orvieto@sheba.health.gov.il.
authors: Raoul
authors: R
authors: Orvieto
mesh_terms: D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000009:adverse effects* / Q000378:metabolism; D005260:Female; D005307:Fertilization in Vitro; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000009:adverse effects / Q000819:agonists / Q000037:antagonists & inhibitors; D006801:Humans; D008183:Luteal Phase; D054315:Oocyte Retrieval; D009865:Oocytes / Q000187:drug effects / Q000254:growth & development*; D016471:Ovarian Hyperstimulation Syndrome / Q000188:drug therapy* / Q000473:pathology; D010062:Ovulation Induction; D011247:Pregnancy; D018873:Pregnancy Rate; D027724:Reproductive Techniques, Assisted
chemical_list: D006063:Chorionic Gonadotropin; D007987:Gonadotropin-Releasing Hormone